Regulatory Watch
Mar 2026: NPR covers peptide reclassification (March 26) — mainstream audience discovers peptide market Mar 2026: 29 days post-RFK announcement: FDA has STILL not published reclassification — no Federal Register notice, no updated list Mar 2026: SAFE Drugs Act filed as H.R. 6509 — bipartisan bill would ban RUO sales of compounds identical to FDA-approved drugs Mar 2026: PolitiFact publishes peptide safety fact-check — documents gap between marketing claims and published evidence Mar 2026: Hims & Hers vendor profile added — NYSE-listed telehealth company building peptide manufacturing in California Mar 2026: 30+ clinic websites publishing reclassification articles — all financially conflicted, none independent Mar 2026: BREAKING: Peptide Sciences shuts down operations (March 6) — largest grey-market vendor gone Mar 2026: Finnrick data: Peptide Sciences BPC-157 scored A, but retatrutide scored E with counterfeit flagged across 37 samples Mar 2026: MMM Online: 'Get ready for the peptides gold rush' — pharma trade media covers market explosion Mar 2026: Jay Campbell: 'Federal government has decided RUO peptide manufacturing can no longer sell injectable peptides' Mar 2026: Grips Intelligence: Peptide Sciences was doing $7.4M/month in sales before shutdown — market vacuum now open Mar 2026: All American Peptide owners plead guilty — $3M+ forfeitures. Tailor Made Compounding: $1.79M forfeiture. June 2025: FDA raids Amino Asylum warehouse; website goes offline, operations cease Feb 2025: FDA declares semaglutide shortage resolved — compounding exception ends Sept 2025: FDA issues 50+ warning letters to GLP-1 compounders; DOJ involvement confirmed Nov 2025: Alabama obtains TRO against GLP-1 distributors — first state-level injunctive relief Sept 2023: FDA moves BPC-157, TB-500, and 15 other peptides to Category 2 — compounding prohibited Dec 2024: PCAC votes against allowing compounding of ipamorelin, MK-677, CJC-1295, AOD-9604 Jan 2025: FDA eliminates Category 2/3 system; prohibited substances remain prohibited Feb 2026: STAT News: 35 of 36 BPC-157 studies are animal-only from single lab with undisclosed conflicts 2025: Chinese peptide imports to US double to $328M; online peptide advertising up 678% since 2022 Mar 2026: NPR covers peptide reclassification (March 26) — mainstream audience discovers peptide market Mar 2026: 29 days post-RFK announcement: FDA has STILL not published reclassification — no Federal Register notice, no updated list Mar 2026: SAFE Drugs Act filed as H.R. 6509 — bipartisan bill would ban RUO sales of compounds identical to FDA-approved drugs Mar 2026: PolitiFact publishes peptide safety fact-check — documents gap between marketing claims and published evidence Mar 2026: Hims & Hers vendor profile added — NYSE-listed telehealth company building peptide manufacturing in California Mar 2026: 30+ clinic websites publishing reclassification articles — all financially conflicted, none independent Mar 2026: BREAKING: Peptide Sciences shuts down operations (March 6) — largest grey-market vendor gone Mar 2026: Finnrick data: Peptide Sciences BPC-157 scored A, but retatrutide scored E with counterfeit flagged across 37 samples Mar 2026: MMM Online: 'Get ready for the peptides gold rush' — pharma trade media covers market explosion Mar 2026: Jay Campbell: 'Federal government has decided RUO peptide manufacturing can no longer sell injectable peptides' Mar 2026: Grips Intelligence: Peptide Sciences was doing $7.4M/month in sales before shutdown — market vacuum now open Mar 2026: All American Peptide owners plead guilty — $3M+ forfeitures. Tailor Made Compounding: $1.79M forfeiture. June 2025: FDA raids Amino Asylum warehouse; website goes offline, operations cease Feb 2025: FDA declares semaglutide shortage resolved — compounding exception ends Sept 2025: FDA issues 50+ warning letters to GLP-1 compounders; DOJ involvement confirmed Nov 2025: Alabama obtains TRO against GLP-1 distributors — first state-level injunctive relief Sept 2023: FDA moves BPC-157, TB-500, and 15 other peptides to Category 2 — compounding prohibited Dec 2024: PCAC votes against allowing compounding of ipamorelin, MK-677, CJC-1295, AOD-9604 Jan 2025: FDA eliminates Category 2/3 system; prohibited substances remain prohibited Feb 2026: STAT News: 35 of 36 BPC-157 studies are animal-only from single lab with undisclosed conflicts 2025: Chinese peptide imports to US double to $328M; online peptide advertising up 678% since 2022

Peptide Sciences

peptidesciences.com ↗
Founded: 2012 HQ: Henderson, NV Last reviewed: March 14, 2026
F
Overall Grade
Transparency 72/100
Testing 68/100
Pricing 55/100
Reputation 80/100
Compliance 50/100
Publishes COA Yes
Third-Party Testing Yes
FDA Warning Letters 0
Product Types injectable, lyophilized-powder, research-chemical
VENDOR SHUTDOWN — March 6, 2026

Peptide Sciences voluntarily shut down operations on March 6, 2026. The company is no longer selling products. Do not enter payment information on any site claiming to be Peptide Sciences — Finnrick has confirmed that any site still operating under this name is fraudulent. If you have unfulfilled orders, initiate a chargeback with your bank immediately.

Full shutdown analysis →

What Happened

On March 6, 2026 at approximately 2:00 PM Eastern, peptidesciences.com went offline and was replaced with a single message:

“After careful consideration, Peptide Sciences has made the decision to voluntarily shut down operations and discontinue the sale of our research products. We are deeply grateful for your trust and support. Thank you for being part of the Peptide Sciences community.”

No further explanation. No refund process. No mention of outstanding orders or customer data.

Why It Matters

Peptide Sciences was the largest grey-market research peptide vendor in the United States. At its peak, the company was generating $7.4 million in monthly online sales (December 2025, per Grips Intelligence) with over one million website sessions per month. Their catalog covered dozens of peptides including BPC-157, TB-500, CJC-1295, ipamorelin, semaglutide, tirzepatide, and retatrutide.

The word “voluntarily” in their shutdown notice is the most revealing detail. Dr. Steven Murphy, writing on Substack, called the closure “something quietly seismic” and observed that Peptide Sciences “existed in the strange legal twilight that has defined the peptide market for years.” The company appears to have read the enforcement trajectory — FDA raids, DOJ prosecutions, ITC exclusion orders, the SAFE Drugs Act — and chosen to close before regulators forced them to.

Prior Assessment (Pre-Shutdown)

PeptideExaminer rated Peptide Sciences B+ prior to the shutdown — the highest grade in our vendor directory. That assessment was based on:

What they did well: Comprehensive COAs published for most products. Claimed WHO/GMP and ISO-certified manufacturing partners. Broad product catalog. Consistent (if expensive) pricing. Long operating history (10+ years). Responsive customer service.

What concerned us: No independent endotoxin testing published. “Research use only” legal positioning increasingly untenable. Payment processing was unstable — the company relied on Venmo, Zelle, Cash App, and cryptocurrency because traditional processors kept cutting them off. That payment instability was itself a red flag about the sustainability of the business model.

Finnrick Testing Record

Finnrick’s independent testing of 123 Peptide Sciences samples across 10 products revealed significant quality inconsistency:

PeptideFinnrick RatingAvg ScoreSamples Tested
IpamorelinA9.2/109
PT-141A
BPC-157A7.8/10
CJC-1295E4.3/10
TesamorelinE
RetatrutideE37 (counterfeit flagged Nov 2025)

The pattern is telling: well-established, simpler peptides tested well. Newer, more complex compounds — especially retatrutide — were significantly below standard, with evidence of counterfeits entering the supply chain.

This data reinforces a point PeptideExaminer has made consistently: even the “best” grey-market vendors operate without the quality controls that regulated pharmaceutical manufacturing provides. A B+ in the grey market was never equivalent to pharmaceutical-grade.

What This Means for Former Customers

Immediate steps:

  • Do not buy from any site claiming to be Peptide Sciences
  • If you have unfulfilled orders, contact your bank for a chargeback
  • If you have remaining product, note the lot numbers and store properly (lyophilized powder at -20°C; reconstituted at 2-8°C, use within 30 days)

Transition options:

  • Compounding pharmacies: If the FDA formally reclassifies Category 2 peptides to Category 1 (still pending), licensed 503A/503B pharmacies will be the safest source. Requires a physician prescription. Typical cost: $150-300/month for BPC-157.
  • Telehealth platforms: Hims & Hers, Ro, and multiple smaller platforms now offer physician-supervised peptide protocols. Higher cost than grey market but legally protected and quality-verified.
  • Other grey-market vendors: Still operating, but the enforcement trajectory is clear. PeptideExaminer maintains vendor ratings for remaining grey-market vendors, but we strongly encourage transition to regulated channels.

The Larger Pattern

Peptide Sciences is not an isolated case. The grey-market model for injectable peptides is under sustained, coordinated pressure from federal enforcement:

  • Amino Asylum: FDA warehouse raid, June 2025. Shut down overnight.
  • All American Peptide: Owners pleaded guilty to conspiracy. $3M+ forfeitures.
  • Tailor Made Compounding: Federal conviction. $1.79M forfeiture.
  • Prime Peptides, SwissChems, Xcel Peptides, Summit Research: FDA warning letters, December 2024.
  • Strate Labs, Arctic Peptides, Triggered Brand: ITC cease and desist orders, January 2025.
  • 7+ vendors shut down throughout 2025.

The pattern is unmistakable: the regulatory and legal framework that tolerated the “research use only” model is collapsing. Peptide Sciences — the largest, most recognizable, highest-rated vendor in the space — chose to exit rather than wait for the collapse to reach them.


This profile was originally published as a vendor review with a B+ rating. It has been updated to reflect the March 6, 2026 shutdown. PeptideExaminer’s original rating methodology and scoring are preserved above for transparency.